GlaxoSmithKline LLC v. Teva Pharmaceuticals USA, Inc.

  1. July 07, 2021

    5 Patent Cases To Watch In The Second Half Of 2021

    The U.S. Supreme Court will be deciding later this year whether to take up a highly controversial patent eligibility case, while a California federal court mulls whether discretionary denial precedent at the Patent Trial and Appeal Board is legal. Here are five cases in patent attorneys' sights for the rest of the year.

  2. February 23, 2021

    Fed. Circ. Tailors Arguments After Teva Skinny Label Outcry

    A Federal Circuit panel zeroed in Tuesday on facts specific to whether Teva induced infringement of GlaxoSmithKline's drug Coreg in a do-over hearing after the panel's initial decision drew criticism that it ended a labeling practice expressly allowed under the Hatch-Waxman Act.

  3. February 09, 2021

    Fed. Circ. Panel Walks Back $235M Skinny Label Ruling

    A Federal Circuit panel on Tuesday vacated its October finding that Teva induced infringement of a patent covering GlaxoSmithKline's drug Coreg to the tune of $235 million and set a new round of oral arguments in the high-profile fight over so-called skinny labels.

  4. December 16, 2020

    Generics 'Urgently' Call On Fed. Circ. To Protect Skinny Labels

    The Federal Circuit has turned a "safe harbor" that allows generic-drug makers to sell patent-protected drugs for off-patent uses into "dangerous waters," the generics industry told the full court Wednesday, backing Teva's bid to get the induced infringement case taken up.

  5. December 02, 2020

    Teva Says Fed. Circ. Made Skinny Label Law 'A Dead Letter'

    The Federal Circuit rendered a section of the Hatch-Waxman Act that allows generic-drug makers to sell patent-protected drugs for unpatented uses "a dead letter" when it revived GlaxoSmithKline's $235 million induced infringement verdict, Teva warned the court on Wednesday, petitioning the full court to rehear what it called the Federal Circuit's "most important infringement decision in years."

  6. October 07, 2020

    Generics Worry Fed. Circ. Blew Up 'Routine' Labeling Practice

    The Federal Circuit's recent decision to revive a $235 million induced infringement verdict against Teva has left generic-drug makers scared that they'll be effectively barred from selling patent-protected drugs for approved, off-patent uses.

  7. October 02, 2020

    Split Fed. Circ. Revives GSK's $235M Win Against Teva

    The Federal Circuit on Friday revived a $235 million verdict against Teva Pharmaceuticals for inducing infringement of a patent covering GlaxoSmithKline LLC's heart disease drug Coreg. However, the ruling was accompanied by a scathing dissent from the court's top judge.